|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| YSYQMALtPVVVTLW SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 448476 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Regulatory protein: | |
| Kinases, in vitro: | |
| Treatments: | |
| Downstream Regulation | |
|---|---|
| Effects of modification on CDK4: | |
| Effects of modification on biological processes: | |
| Disease / Diagnostics Relevance | |
|---|---|
| Relevant diseases: | |
| References | |
|---|---|
|
Paternot S, et al. (2022) Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Mol Oncol
36453028 Curated Info |
|
|
Gharbi SI, et al. (2022) Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy. NPJ Breast Cancer 8, 126
36446794 Curated Info |
|
|
Snaider S, Zheng Y, Hearing P (2022) Rb-E2F-HDAC Repressor Complexes Control Interferon-Induced Repression of Adenovirus To Promote Persistent Infection. J Virol 96, e0044222
35546119 Curated Info |
|
|
Raspé E, et al. (2017) CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med 9, 1052-1066
28566333 Curated Info |
|
|
Colleoni B, et al. (2017) JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21. Oncogene 36, 4349-4361
28368408 Curated Info |
|
|
Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451 Curated Info |
|
|
Bisteau X, et al. (2013) CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point. PLoS Genet 9, e1003546
23737759 Curated Info |
|
|
Guo A (2011) CST Curation Set: 12167; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info |
|
|
Guo A (2011) CST Curation Set: 12017; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
|
Blancquaert S, et al. (2010) cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol 24, 1453-68
20484410 Curated Info |
|
|
Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195 Curated Info |
|
|
Takaki T, et al. (2009) The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A 106, 4171-6
19237555 Curated Info |
|
|
Bockstaele L, et al. (2006) Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". Mol Cell Biol 26, 5070-85
16782892 Curated Info |
|
|
Kahl CR, Means AR (2004) Regulation of cyclin D1/Cdk4 complexes by calcium/calmodulin-dependent protein kinase I. J Biol Chem 279, 15411-9
14754892 Curated Info |
Developed with grants from
|
and literature mining with Linguamatics
|
PhosphoSite, created by Cell Signaling Technology is licensed under a Creative
Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
|
©2003-2019 Cell Signaling Technology, Inc.
